A study reveals attrition rates in patients with geographic atrophy on complement inhibitor therapies, highlighting the need for improved treatment adherence strategies.
Deepak Sambhara, MD
Advertisement
Deepak Sambhara, MD, is partner and medical director of research at the Eye Clinic of Wisconsin.
Articles by Deepak Sambhara, MD
At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid outcomes analysis of patients who participated in the phase 3 clinical trial PULSAR.
Advertisement
Latest Updated Articles
Q&A: Deepak Sambhara, MD, discusses real-world follow-up for patients with GAPublished: June 6th 2025 | Updated:
Envision Summit 2025: PULSAR phase 3 trial 96-week post-hoc analysisPublished: February 16th 2025 | Updated:
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Treating myopia today: US-focused treatments, challenges, and global insights
2
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
3
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
4
FDA clears BVI’s FineVision HP trifocal IOL for the US market
5
.png "Optometry Times"){kind=logo}
